PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSE

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ABSTRACT HYPOTHESES The farnesyltransferase inhibitor, R115777, will function as a radiosensitizing agent in patients with brainstem gliomas. In addition, ras-mediated anti-tumor activity will be observed in brainstem gliomas following treatment with R115777. SPECIFIC AIMS Primary Objectives 1. To estimate the MTD of R115777 when administered to pediatric patients with nondisseminated, diffuse, intrinisc brainstem gliomas concurrently with radiation therapy with a limited dose escalation. 2. To assess the efficacy of R115777 treatment in combination with radiation therapy for patients with non-dissemianted, diffuse, intrinsic pontine gliomas as measured by progression-free survival. Secondary Objectives 3. To characterize toxicities associated with R115777 in combination with radiation therapy. 4. To characterize radiographic changes in brainstem gliomas treated with radiation and R115777 using MRI, MRS, perfusion and diffusion imaging and PET scans.